MedTrace Logo

A Phase I Study of XJ103 in Chinese Healthy Subjects

NCT06026748 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2024-03-27

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.

Conditions

  • Pneumococcal Disease

Interventions

DRUG

XJ103 Injection

XJ103 is a humanized monoclonal antibody.

DRUG

Placebo

Placebo contains only excipients.

Sponsors & Collaborators

  • Starmab biologics（Shanghai）Co,.ltd

    lead INDUSTRY

Principal Investigators

  • Ding xueying · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-12
Primary Completion
2024-12-24
Completion
2025-03-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06026748 on ClinicalTrials.gov